Ginkgo Bioworks Holdings (DNA) EBITDA Margin Growth (1y) (2021 - 2026)

Ginkgo Bioworks Holdings (DNA) EBITDA Margin Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1,552.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 1,536.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -170.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1,049.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Ginkgo Bioworks Holdings 517.16 Mn 373.30 Mn 16.38 Mn -15,471.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -15,471.00
Dec 31, 2025 2,443.00
Sep 30, 2025 -16,979.00
Jun 30, 2025 26,453.00
Mar 31, 2025 25,732.00
Dec 31, 2024 -16,302.00
Sep 30, 2024 45,468.00
Jun 30, 2024 -16,809.00
Mar 31, 2024 -20,178.00
Dec 31, 2023 16,162.00
Sep 30, 2023 46,971.00
Jun 30, 2023 21,936.00
Mar 31, 2023 13,370.00
Dec 31, 2022 89,966.00
Sep 30, 2022 -95,202.00
Jun 30, 2022 -31,055.00
Mar 31, 2022 -27,152.00
Dec 31, 2021 -96,021.00
Sep 30, 2021 22,434.00